Reduction in CUA MRI Lesions in the First 6 Months after Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Subgroup Analysis

被引：0

作者：

De Stefano, Nicola ^{[1
]}

Barkhof, Frederik ^{[2
,3
]}

Montalban, Xavier ^{[4
]}

Achiron, Anat ^{[5
]}

Derfuss, Tobias ^{[6
]}

Chan, Andrew ^{[7
]}

Hodgkinson, Suzanne ^{[8
]}

Prat, Alexandre ^{[9
]}

Leocani, Letizia ^{[10
]}

Schmierer, Klaus ^{[11
,12
]}

Sellebjerg, Finn ^{[13
]}

Vermersch, Patrick ^{[14
]}

Wiendl, Heinz ^{[15
]}

Keller, Birgit ^{[16
]}

Roy, Sanjeev ^{[17
]}

机构：

[1] Univ Siena, Dept Neurol & Behav Sci, Siena, Italy

[2] Vrije Univ Amsterdam, Med Ctr, Dept Radiol, Amsterdam, Netherlands

[3] UCL Inst Neurol, London, England

[4] Hosp Univ Vall dHebron, Ctr Esclerosi Multiple Catalunya Cemcat, Dept Neurol Neuroimmunol, Barcelona, Spain

[5] Sheba Acad Med Ctr, Multiple Sclerosis Ctr, Ramat Gan, Israel

[6] Univ Hosp Basel, Dept Neurol, Basel, Switzerland

[7] Univ Bern, Univ Hosp Berne, Bern, Switzerland

[8] Univ New South Wales Med, Ingham Inst Appl Med Res, Kensington, NSW, Australia

[9] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada

[10] Univ Vita Salute San Raffaele, Expt Neurophysiol, INSPE, Milan, Italy

[11] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England

[12] Royal London Hosp, Barts Hlth NHS Trust, Clin Board Med Neurosci, London, England

[13] Copenhagen Univ Hosp, Rigshosp, Dept Neurol, Danish MS Ctr, Copenhagen, Denmark

[14] Univ Lille, CHU Lille, INSERM, U1172,LilNCog,FHU Imminent, Lille, France

[15] Univ Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany

[16] Merck KGaA, Darmstadt, Germany

[17] Merck, Aubonne, Switzerland

来源：

NEUROLOGY | 2021年 / 96卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

1921

引用

页数：6

共 33 条

[31] COST-UTILITY ANALYSIS OF NATALIZUMAB AS FIRST-LINE TREATMENT OF HIGHLY-ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM
Alves, J.
Machado, M.
VALUE IN HEALTH, 2015, 18 (07) : A878 - A878
[32] Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study
Arnold, Douglas L.
Barnett, Michael
Comi, Giancarlo
Giovannoni, Gavin
Pelletier, Daniel
Rovira, Alex
Schippling, Sven
Van Wijmeersch, Bart
Margolin, David H.
Thangavelu, Karthinathan
Traboulsee, Anthony
NEUROLOGY, 2017, 88
[33] Alemtuzumab Suppresses MRI Disease Activity Over 6 Years in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy: CARE-MS II
Schippling, Sven
Traboulsee, Anthony
Barnett, Michael
Comi, Giancarlo
De Seze, Jerome
Giovannoni, Gavin
Pelletier, Daniel
Rovira, Alex
Margolin, David H.
Thangavelu, Karthinathan
Arnold, Douglas L.
NEUROLOGY, 2017, 88

← 1 2 3 4 →